ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour

Published On: 8/27/2024

ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour

Team members Kathleen Hurwtiz, ScD, Catherine Wiener, and Chase Latour helped author a new Target RWE study presented at ISPE 2024 titled “Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study.”

The study investigates the potential biases in sequential nested trial emulations, a study designed for rare disease research. Using a simulation framework, the authors compared the results of sequential nested trial emulation to those of single-point randomized trials. Watch this research presentation for valuable insights on using sequential nested trial emulations, highlighting the importance of careful study design and analysis to ensure accurate results:

About Target RWE

As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.

Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com

Contact:

Kayla Slake
Marketing Manager

kslake@targetrwe.com

984.234.0268 ext 205